-
CAF EV lncRNA Drives HLA-A Loss in Pancreatic Cancer
2026-09-14
The reference study identifies CAF-derived extracellular vesicle lncRNA RP11-161H23.5 as a mediator of pancreatic ductal adenocarcinoma immune evasion. It links this RNA to CNOT4-dependent shortening of the HLA-A mRNA poly(A) tail and proposes engineered extracellular vesicles for siRNA delivery as a therapeutic strategy.
-
GLT-1, CB1-CREB, and Cognitive Recovery After TBI
2026-09-14
A 2025 mouse study links traumatic brain injury to transient loss of astrocytic GLT-1 through a 2-AG–CB1–CREB mechanism, connecting impaired glutamate clearance with neuronal apoptosis and cognitive dysfunction. Its use of AM281 alongside behavioral, histological, and molecular assays provides a pharmacological framework for testing CB1-dependent regulation of excitotoxicity.
-
HyperScribe™ All in One mRNA Synthesis Kit
2026-09-13
The HyperScribe All in One mRNA Synthesis Kit supports controlled ARCA-capped, polyadenylated transcript production for translation, vaccine, and RNA-function studies. This guide goes beyond workflow description to connect transcript design and quality control with the immune-engineering lessons of a 2026 spleen-targeted HCC mRNA vaccine study.
-
Hepatic sEH, Nrf2, and Osteoporosis
2026-09-12
The reference study identifies a liver–bone axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppresses Nrf2 signaling, and promotes osteoclast differentiation. By combining clinical samples, ovariectomy-induced osteoporosis, liver-specific knockdown, pharmacological inhibition, transcriptomics, and cell-based assays, the work provides a mechanistic framework for studying lipid–redox control of bone resorption.
-
Simvastatin: HepG2 Lipidomics Workflow
2026-09-11
Simvastatin (Zocor) provides a practical benchmark for linking HMG-CoA reductase inhibition with cholesterol handling, lipid accumulation, and cancer-cell phenotypes. This workflow shows how to combine controlled dosing, orthogonal lipid assays, and untargeted lipidomics while avoiding common solubility and prodrug-activation errors.
-
Molecular Regulation of TRPM3 by Neurosteroids
2026-09-11
The reference study combines cryo-electron microscopy, electrophysiology, molecular dynamics, and mass spectrometry to define how PregS, CIM0216, and primidone regulate the TRPM3 ion channel. Its structures connect ligand-binding sites with channel gating and disease-associated gain-of-function mutations, providing a mechanistic framework for TRPM3-directed analgesic and neurodevelopmental research.
-
PD 0332991 in Gastric Cancer Assembloids
2026-09-10
PD 0332991 (Palbociclib HCl) is examined here as a mechanistic probe for patient-derived gastric cancer assembloids, not simply as a conventional CDK4/6 inhibitor. Learn how stromal context, Rb status, and assay design can reshape interpretation of antiproliferative responses.
-
Spatial Metabolomics Maps Lipid Changes in POCD
2026-09-10
This rat study combines cardiopulmonary bypass, behavioral testing, spatial metabolomics, enzyme imaging, and electron microscopy to define hippocampal lipid abnormalities associated with postoperative cognitive dysfunction. Its rescue experiments with Docosahexaenoic Acid (DHA) and myriocin link altered lipid regulation to synaptic damage and improved cognitive performance, while also highlighting the limitations of translating an animal model into clinical prevention.
-
Bromodomain Inhibitor (+)-JQ1: Assay Workflows
2026-09-09
Bromodomain Inhibitor, (+)-JQ1 converts BET biology into practical assays for transcriptional control, apoptosis, and ferroptosis sensitization. This workflow-led guide shows how to pair BRD4 inhibition with ROS and FSP1 measurements while avoiding common dosing, solvent, and endpoint errors.
-
JC-1 Mitochondrial Membrane Potential Assay
2026-09-09
The JC-1 Mitochondrial Membrane Potential Assay Kit enables ratiometric analysis of mitochondrial depolarization while clarifying what ΔΨm can—and cannot—prove about apoptosis. This guide connects assay design with recent hypoxia-activated cancer therapy research and emphasizes controls, interpretation, and translational limitations.
-
JC-1 Mitochondrial Membrane Potential Assay Kit
2026-09-08
Learn how the JC-1 Mitochondrial Membrane Potential Assay Kit converts ΔΨm changes into interpretable evidence for mitochondrial function analysis. This guide connects ratiometric JC-1 measurements with apoptosis research and the mechanistic questions raised by hypoxia-activated cancer therapeutics.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-08
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measures capture different components of an in vitro anticancer response. The framework improves interpretation of drug screens by separating proliferative arrest from cell killing and by considering their relative timing, rather than treating every reduction in viability as equivalent.
-
K+ Channel Blockade and Renal Blood Flow in Sepsis
2026-09-07
This study showed that ATP-sensitive and calcium-activated potassium channel blockade can worsen renal blood-flow reductions when septic rats receive norepinephrine or phenylephrine. Its key contribution is a renal vascular analysis that separates baseline channel effects from the response to vasopressor challenge, highlighting potential risks of nonspecific channel inhibition during sepsis.
-
WST-8 Glucose Uptake Assay Kit Workflow
2026-09-07
Turn transporter activity into a rapid, non-radioactive 450 nm readout for cancer metabolism research, diabetes models, and delivery studies. This workflow also shows how to use the assay as a downstream phenotypic check when ion supplementation changes CPP–nucleic acid nanoparticle performance.
-
Miltefosine Workflows for PI3K/Akt and Neutrophils
2026-09-05
Miltefosine is a practical pathway-probing tool for comparing PI3K/Akt inhibition with Ras/MEK/ERK-driven neutrophil differentiation. This workflow-focused guide connects acute signaling assays, hematopoietic recovery models, and oncology readouts while highlighting controls, dosing logic, and troubleshooting strategies.